Treatment of androgen excess in females: Yesterday, today and tomorrow

References

• Montagna W., Scott E. J. The anatomy of hair follicle. The Biology of Hair Growth , W. Montagna, E. J. Scott. Academic Press, New York 1958; 39–64
   Google Scholar
• Hashimoto K. The structure of human hair. Clin. Dermatol. 1988; 6: 7–21
   PubMed Web of Science ®Google Scholar
• Danforth C. H., Trotter M. The distribution of body hair in white subjects. Am. J. Phys. Anthrop. 1982; 5: 259
   Google Scholar
• Van Scott E. H. Physiology of hair growth. Clin. Obstet. Gynecol. 1964; 7: 1062
   Web of Science ®Google Scholar
• Itami S., Kurata S., Sonoda T., Takayasu S. Mechanism of action of androgens in dermal papilla cells. Ann. New York Ace. Sci. 1991; 642: 385–95
   PubMed Web of Science ®Google Scholar
• Saitoh M., Sakamoto M. Human hair cycle. J. Invest. Dermatol. 1970; 54: 65–81
   PubMed Web of Science ®Google Scholar
• Tammi R., Santti R. Morphometric analysis of human epidermis treated with testosterone and dehydroepiandrosterone in organ culture. Arch. Dermatol. Res. 1989; 281: 417
   PubMed Web of Science ®Google Scholar
• Leshin M., Wilson J. Mechanism of androgen-mediated hair growth. Hair Research , C. E. Orfomos, W. Montagna, G. Stuttgen. Springer-Verlag, Berlin 1981; 205–9
   Google Scholar
• Thornton M. J., Messenger A. G., Elliot K., Randall V. A. Effects of androgens on the growth of cultured human dermal papilla cells derived from beard and scalp hair follicles. J. Invest. Dermatol. 1991; 97: 345–8
   PubMed Web of Science ®Google Scholar
• Bardin W. C., Lipsett M. B. Testosterone and androstenedione blood production rates in normal women and women with idiopathic hirsutism or polycystic ovaries. J. Clin. Invest. 1967; 46: 891–902
   PubMed Web of Science ®Google Scholar
• Serafini P., Lobo R. A. Increased 5 a-reductase activity in idiopathic hirsutism. Fertil. Steril. 1972; 43: 74–9
   Google Scholar
• Matted R. K., Stanczyk F. Z., Gentzschein E. E., Delgado C., Lobo R. A. Androgen sulfate and glucuronide conjugates in non-hirsute and hirsute women with polycystic ovarian syndrome. Am. J. Obstet. Gynecol. 1998; 161: 1704–9
   Google Scholar
• Ebling F. J. G., Hale P. A., Randall V. A. Hormones and hair growth. Biochemistry and Physiology of the Skin. , L. A. Goldsmith. Clarendon Press, Oxford 1991
   Google Scholar
• Hamilton J. B. Age, sex and genetic factors in the regulation of hair growth in man: a comparison of Caucasian and Japanese populations. The Biology of Hair Growth , W. Montagna, R. A. Ellis. Academic Press, New York 1958; 399–433
   Google Scholar
• Ferriman D., Gallwey J. D. Clinical assessment of body hair growth in women. J. Clin. Endocrinol. Metab. 1961; 21: 1440
   PubMed Web of Science ®Google Scholar
• McKnight E. The prevalence of hirsutism in young women. Lancet 1964; 1: 400
   Web of Science ®Google Scholar
• Lorenzo E. M. Familial study of hirsutism. J. Clin. Endocrinol. Metab. 1970; 31: 556
   PubMed Web of Science ®Google Scholar
• Madanes A. E., Novotny M. The vellus index: a new method of assessing hair growth. Fertil. Steril. 1987; 48: 1064
   PubMed Web of Science ®Google Scholar
• Ebling F. J. G., Randall V. A. Hormonal action on hair follicles and associated glands. Methods in Skin Research , D. Skerrow, C. J. Skerrow. John Wiley, New York 1985; 297–327
   Google Scholar
• Seago S. V., Ebling F. J. G. The hair cycle on the human thigh and upper arm. Br. J. Dermatol 1985; 113: 9–16
   PubMed Web of Science ®Google Scholar
• Greemblatt R. B., Gambrell R. D. The ovary as a source of androgens A. The polycystic ovary B. Masculinising ovarian tumors. The Cause and Management of Hirsutism , V. B. Greemblatt, V. B. Mahesch, R. D. Gambrell. Parthenon Press, CarnforthUK 1987; 83–97
   Google Scholar
• Derogatis L. R., Rose L. I., Shulman L. H., Lazarus L. A. Serum androgens and psychopathology in hirsute women. J. Psychosom. Obstet. Gynecol. 1993; 14: 269–82
   PubMed Web of Science ®Google Scholar
• Lobo R., Granger L., Goebelsmann U., Mishell D. Psychological stress and increases in urinary norepinephrine metabolites, platelet serotonin, and adrenal androgens in women with polycystic ovary syndrome. Am. J. Obstet. Gynecol. 1985; 15: 496–503
   Google Scholar
• Chavis W. M., La Ferla J. J., Brown J. C., Keith R. B. Psychosexual aspects of virilization syndrome. Int. J. Gynecol. Obstet. 1989; 30: 389–94
   PubMed Web of Science ®Google Scholar
• Faure M., Drapier-Faure E. Hormonal assessment in a woman with acne and alopecia. Rev. Fr. Gynecol. Obstet. 1992; 87: 331–4
   PubMedGoogle Scholar
• Jebraili R., Kaur S., Kanwar A. J., Kataria S., Dash R. J. Hormone profile and polycystic ovaries in acne vulgaris. Ind. J. Med. Res. 1994; 100: 73–6
   PubMed Web of Science ®Google Scholar
• Vewiau P., Husson C., Chivot M., Brerault J. L., Fiet J., Julien R., Villette J. M., Hardy N., Cathelineau G. Androgen excess in women with acne alone compared with women with acne and/or hirsutism. J. Invest. Dermatol. 1990; 94: 279–83
   PubMed Web of Science ®Google Scholar
• Medda F., Nieddu R., Fiore R., Marcello C., Lecca U. Hormonal profile and androgen status during the menstrual cycle in women with acne. Clin. Exp. Obstet. Gynecol. 1988; XV: 137–42
   Google Scholar
• de Raeve L., de Shepper J., Smitz J. Prepubertal acne: a cutaneous marker of androgen excess. J. Am. Acad. Dermatol. 1995; 32: 181–4
   PubMed Web of Science ®Google Scholar
• Rosenfield R. L., Lucky A. W. Acne, hirsutism and alopecia in adolescent girls. Clinical expression of androgen excess. Endocrinol. Metab. Clin. N. Am. 1993; 22: 507–32
   PubMed Web of Science ®Google Scholar
• Braun-Falco O., Plewig G., Wolf H. H., Winkelman R. K. Diseases of the sebaceous follicles. Dermatology . Springer-Verlag, Berlin 1988; 716–21
   Google Scholar
• Redmond G. P., Bergfeld W. F. Diagnostic approach to androgen disorders in women: acne, hirsutism and alopecia. Cleve. Clin. J. Med. 1990; 57: 423–7
   Google Scholar
• Sheehan-Dare R. A., Hughes B. R., Cunliffe W. Y. Clinical markers of androgenicity in acne vulgaris. Br. J. Dermatol. 1988; 119: 723–30
   PubMed Web of Science ®Google Scholar
• Lucky A. W. Hormonal correlates of acne and hirsutism. Am. J. Med. 1995; 16: 898–46
   Google Scholar
• Levell M. J., Cawood M. L., Burke B., Cunliffe W. J. Acne is not associated with abnormal plasma androgens. Br. J. Dermatol. 1989; 120: 649–54
   PubMed Web of Science ®Google Scholar
• Fiet J., Gosling J. P., Soliman H., Galons H., Boudou P., Aubin P., Belanger A., Villette J. M., Julien R., Brerault J. L. Hirsutism and acne in women: coordinated radioimmunoassay for eight relevant plasma steroids. Clin. Chem. 1994; 40: 2296–305
   PubMed Web of Science ®Google Scholar
• Hamilton J. B. Patterned loss of hair in man; types and incidence. Ann. N. Y. Acad. Sci. 1951; 53: 708–28
   PubMed Web of Science ®Google Scholar
• Norwood O. T. Male pattern baldness: classification and incidence. South. Med. J. 1975; 68: 1359–65
   PubMed Web of Science ®Google Scholar
• Setty L. R. Hair patterns of the scalp of white and negro males. Am. J. Phys. Anthropol. 1970; 33: 49–55
   PubMed Web of Science ®Google Scholar
• Randall V. A., Ebling F. J. G. Seasonal changes in human hair growth. Br. J. Dermatol 1991; 124: 146–51
   PubMed Web of Science ®Google Scholar
• Bradfield R. B., Bailey M. A., Cordano J. A. Hair-root changes in andean indian children during marasmic kwashiorkor. Lancet 1968; II: 1169–70
   Google Scholar
• Bradfield R. B., Cordano A., Graham G. G. Hair-root adaptation to marasmus in andean indian children. Lancet 1969; II: 1395–7
   Google Scholar
• Sims R. T. Hair growth in kwashiorkor. Arch. Dis. Child. 1967; 42: 397–400
   PubMed Web of Science ®Google Scholar
• Bergfeld W. F. Androgenic alopecia: an autosomal dominant disorder. Am. J. Med. 1995; 16: 958–88
   Google Scholar
• Randall V. A., Thornton M. J., Messenger A. G. Cultured dermal papilla cells from androgen-dependent human follicles contain more androgen receptors than those from non-balding areas. J. Endocrinol. 1992; 133: 141–7
   PubMed Web of Science ®Google Scholar
• Orentrich N. Scalp in hair replacement in man. Advances in Biology of Skin , W. Montagna, R. L. Dobson. Pergamon Press, London, 9: 99–108
   Google Scholar
• Ludwig E. Classification of androgenic alopecia occurring in the female sex. Br. J. Dermatol. 1977; 97: 247–54
   PubMed Web of Science ®Google Scholar
• Eckert J., Church R. E., Ebling F. J., Munro D. S. Hair loss in women. Br. J. Dermatol. 1967; 79: 543–8
   PubMed Web of Science ®Google Scholar
• Jakson D., Church R. E., Ebling F. J. Hair diameter in female baldness. Br. J. Dermatol. 1972; 87: 361–7
   PubMed Web of Science ®Google Scholar
• Zins G. R. History of minoxidil. Clin. Dermatol. 1988; 6: 132–43
   PubMed Web of Science ®Google Scholar
• Roenigh H. H. J. R., Pepper E., Kuruvilla S. Topical minoxidil therapy for hereditary male pattern alopecia. Cutis 1987; 39: 337–42
   PubMed Web of Science ®Google Scholar
• Baden H. P., Grassi A., Kuedar J. The effect of the drug minoxidil on hair growth. The Biology of Wool and Hair , G. E. Rogers, P. J. Reis, K. A. Ward, R. C. Marshall. Chapman & Hall, London 1989; 217–26
   Google Scholar
• Chang F. J., Laufer L. R., Meldrum D. R., de Fazio J., Lu J. K., Vale W. V., Rivier J. E., Judd H. L. Steroid secretion in polycystic ovarian disease after ovarian suppression by a long acting gonadotropin releasing hormone agonist. J. Clin. Endocrinol. Metab. 1983; 56: 897–904
   PubMed Web of Science ®Google Scholar
• Andreyko J. L., Monroe S. E., JafFe R. B. Treatment of hirsutism with gonadotropin releasing hormone agonist (naferalin). J. Clin. Endocrinol. Metab. 1986; 63: 854–9
   PubMed Web of Science ®Google Scholar
• Steingold K., Ziegler D. D., Cedars M., Mel-drum D. R., Lu J. K., Judd H. L. Clinical and hormonal effects of chronic gonadotropin releasing hormone agonist treatment in polycystic ovarian disease. J. Clin. Endocrinol. Metab. 1987; 65: 773–8
   PubMed Web of Science ®Google Scholar
• Rittmaster R. Differential suppression of testosterone and estradiol in hirsute women with the superactive gonadotropin releasing hormone leuprolide. J. Clin. Endocrinol. Metab. 1988; 67: 651–5
   PubMed Web of Science ®Google Scholar
• Carmina E., Stanczyk F. Z., Gentzschein E., Lobo R. A. Time dependent changes in serum 3-α androstanediol glucuronide correlate with hirsutism scores after ovarian suppression. Gynecol. Endocrinol. 1995; 9: 215–20
   PubMed Web of Science ®Google Scholar
• Adashi E. Y. Potential utility of gonadotropin releasing hormone agonists in the management of ovarian hyperandrogenism. Fertil. Steril. 1990; 53: 765–79
   PubMed Web of Science ®Google Scholar
• Karten M. J., Rivier J. E. Gonadotropin releasing hormone analog design: structure-function studies toward the development of agonists and antagonists. Endocr. Rev. 1986; 7: 44–59
   PubMed Web of Science ®Google Scholar
• Clayton R. N. GnRH from physiology to pharmacology. Clin. Endocrinol. 1987; 26: 361–84
   PubMed Web of Science ®Google Scholar
• Rabin D., McNeil L. W. Pituitary and gonadal desensitization after continuous luteinizing hormone-releasing hormone infusion in normal females. J. Clin. Endocrinol. Metab. 1980; 51: 873
   PubMed Web of Science ®Google Scholar
• Falsetti L., Pasinetti E. Treatment of moderate and severe hirsutism by gonadotropin releasing hormone agonists in women with polycystic ovary syndrome and idiopathic hirsutism. Fertil. Steril. 1994; 61: 817–22
   PubMed Web of Science ®Google Scholar
• Carmina E., Lobo R. A. GnRH-agonist therapy for hirsutism is as effective as high dose cyproterone acetate but results in a longer remission. Fertil. Steril. 1995, Suppl., (Abstracts of the 41st Meeting of Reproductive Medicine, Seattle, October 7-12, 1995), abstr. 0.084, 102
   PubMedGoogle Scholar
• de Fazio J., Meldrum D. R., Laufer Vale W. V., Rivier J. E., Lu J. K. H. Induction of hot flashes in menopausal women treated with a long acting GnRH-agonist. J. Clin. Endocrinol. 1983; 35: 342–6
   Google Scholar
• Carmina E., Janni A., Lobo R. A. Physiological estrogen replacement may enhance the effectiveness of the gonadotropin releasing hormone agonist in the treatment of hirsutism. J. Clin. Endocrinol. Metab. 1994; 78: 126–30
   PubMed Web of Science ®Google Scholar
• Lindsay R., Hart D. M., Clark D. M. The minimum effective dose of estrogen for prevention of post-menopausal bone loss. Obstet. Gynecol. 1984; 63: 759–63
   PubMed Web of Science ®Google Scholar
• Elkind-Hirsch K. E., Anania C., Mack M., Malina K. R. Combination gonadotropin releasing hormone agonist and oral contraceptive therapy improves treatment of hirsute women with ovarian hyperandrogenism. Fertil. Steril. 1995; 63: 970–8
   PubMed Web of Science ®Google Scholar
• Morcos R. N., Abdul-Malak M. E., Shikora E., et al. Treatment of hirsutism with a gonadotropin releasing hormone agonist with and estrogen replacement therapy. Fertil. Steril. 1994; 61: 427–31
   PubMed Web of Science ®Google Scholar
• Lemay A., Faure N. Sequential estro-gen-progestin addiction to gonadotropin releasing hormone agonist suppression for the chronic treatment of ovarian hyperandrogenism: a pilot study. J. Clin. Endocrinol. Metab. 1994; 79: 1716–22
   PubMed Web of Science ®Google Scholar
• Steingold K., Judd H., Nieberg R., Lu J., Chang J. Treatment of severe androgen excess due to ovarian hyperthecosis with a long-acting gonadotropin-releasing hormone agonist. Am. J. Obstet. Gynecol. 1986; 154: 1241–7
   PubMed Web of Science ®Google Scholar
• Rivier J. Novel antagonists of GnRH: a compendium of their physiochemical properties, activities, relative potencies and efficacy in humans. GnRH Analogues. The State of the Art , B. Lunenfeld, V. Insler. Parthenon Publishing Group, London 1993; 13–26
   Google Scholar
• Bokser L., Bajusz S., Groot K., Schally A. V. Prolonged inhibition of luteinizing hormone and testosterone levels in male rats with the luteinizing hormone-releasing hormone antagonist SB-75. Proc. Natl Acad. Sci. USA 1990; 87: 7100–4
   PubMed Web of Science ®Google Scholar
• Diedrich K., Diedrich C., Santos E., Zoll C. Al, Hasani S., Reissmann T., Krebs D., Klingmuller D. Suppression of the endogenous luteinizing hormone surge by the gonadotropin-releasing hormone antagonist Cetrorelix during ovarian simulation. Hum. Reprod. 1994; 9: 788–91
   PubMed Web of Science ®Google Scholar
• Schmidt F., Sundaram K., Thau R. B., Bardin C. W. (Ac-D-Nal (2) 1, 4FD-Phe2, D-TRP3, D-Arg6)-LH-RH, a potent antagonist of LH-RH, produces transient edema and behavioral changes in rats. Contraception 1984; 29: 283–9
   PubMed Web of Science ®Google Scholar
• Hahn D. W., McGuire J. L., Vale W. W., Rivier J. Reproductive endocrine and anaphylactoid properties of an LH-RH-antagonist, ORF-18260 (Ac-DNall (2), 4FDPhe2, D-TRP3, D-Arg6)-GnRH. Life Sci. 1985; 37: 505–14
   PubMed Web of Science ®Google Scholar
• Rivier J. E., Porter J., Rivier C. L., Perrin M., Corrigan A., Hook W. A. New effective gonadotropin releasing hormone antagonists with minimal potency for histamine release. in vitro. J. Med. Chem. 1986; 29: 1846–51
   PubMed Web of Science ®Google Scholar
• Nestor J. J., Jr., Tahilramani R., Ho T. I., Goodpasture J. C., Vickery B. H., Ferrnadon P. Design of luteinizing hormone-releasing hormone peptides: Proceedings of the 20th European Peptide Symposium. de Cruyter, Berlin 1988; 592–4
   Google Scholar
• Gonzales-Barcena D., Vadillo-Buenfil M., Garcia-Procel E., Mares G., Bajusz S., Comaru-Schally A. M. Inhibition of LH and FSH release in hypergonadotropic patients with new potent antagonists of LHRH free of anaphylactoid reactions. Endocrine Society Annual Meeting. Seattle, Washington 1989; 450, 21-24 June, Abstract 1712
   Google Scholar
• Bajusz S., Kovacs M., Gazdag M., Bokser L., Karashima T., Csernus V. J., Janaky T., Guoth J., Schally A. V. Highly potent antagonists of luteinizing hormone-releasing hormone free of edematogenic effects. Proc. Natl Acad. Sci. USA 1988; 85: 1637–41
   PubMed Web of Science ®Google Scholar
• Olivennes F., Fanchin R., Bouchard P., de Ziegler D., Taieb J., Selva J., Frydman R. The single or dual administration of the gonadotropin-releasing hormone antagonist Cetrorelix in anin vitro fertilization-embryo transfer program. Fertil. Steril. 1994; 62: 468–76
   PubMed Web of Science ®Google Scholar
• Rabinovici J., Rothman P., Monroe S. E., Neremberg C. A., Jaffe P. Endocrine effects and pharmacokinetic characteristics of a potent new GnRH antagonist (Ganirelix) with minimal histamine-releasing properties: studies in post-menopausal women. J. Clin. Endocrinol. Metab. 1992; 75: 1220–5
   PubMed Web of Science ®Google Scholar
• Ljunqvist A., Feng D., Tang P. F. L., Kubota M., Okamoto T., Hook W. A., Folkers B. Design, synthesis and bioassays of antagonist of LHRH which have high antiovulary activity and release negligible histamine. Biochem. Biophys. Res. Commun. 1987; 148: 849–56
   PubMed Web of Science ®Google Scholar
• Barcena D. G., Buenfil Emilo M. V., Procel G., Arguero L. G., Cornejo I. G., Comaru-Shally A. L., Shally A. V. Inhibition of luteinizing hormone, follicle-stimulating hormone and sex-steroid levels in men and women with a potent antagonist analog of luteinizing hormone-releasing hormone, Cetrorilex(SB-75). Eur. J. Endocrinol 1994; 131: 286–92
   PubMed Web of Science ®Google Scholar
• Gambrell R. D. Regression of polycystic ovaries by estrogen therapy. Obstet. Gynecol. 1976; 47: 569
   PubMed Web of Science ®Google Scholar
• Casey J. H., Burgher H. G., Kent J. R., Kellie A. E., Moxham A., Nabarro J., Nabarro J. D. N. Treatment of hirsutism by adrenal and ovarian suppression. J. Clin. Endocrinol. Metab. 1966; 26: 1370–4
   PubMed Web of Science ®Google Scholar
• Levrant S. G., Barnes R. B. Pharmacology of estrogens. Treatment of Post-Menopausal Women , R. A. Lobo. Raven Press, New York 1994; 57–68
   Google Scholar
• Iperplasia Kurman R. J., Kaminsky P. T., Norris H. J. The behaviour of endometrial hyperplasia: a long-term study of untreated hyperplasia in 170 patients. Cancer 1985; 56: 403–12
   PubMedGoogle Scholar
• Huang S. J., Amparo E. G., Fu J. S. Endometrial hyperplasia: histological classification and behavior. Surg. Pathol. 1988; 1: 215–29
   Google Scholar
• Ormann O., Catt K. J., Schulz K. D., Emons G. Modulatory action of progesterone and progesterone antagonist on hypo-thalamic-pituitary function. Hum. Reprod. 1994; 9: 53–62
   PubMedGoogle Scholar
• Wambach G., Higgins J. R., Kern D. C., Kaufmann W. Interaction of synthetic progestagens with renal mineralo-corticoid receptors. Acta Endocrinol. 1979; 92: 560–7
   PubMedGoogle Scholar
• Landau R. L., Lugibihl K. Inhibition of the sodium retaining influence of aldosterone by progesterone. J. Clin. Endocrinol. Metab. 1958; 18: 1237–45
   PubMed Web of Science ®Google Scholar
• Losert W., Casals-Stenzel J., Buse M. Progestogens with antimineralocorticoid activity. Arzneimittelforschung 1985; 35: 459–71
   PubMed Web of Science ®Google Scholar
• Krattenmacher R., Fromm M. Mineralocorticid and antimineralocorticoid effects of various progestogens on electrogenic Na+ transport in the rat distal colon. in vitro. Acta Endocrinol. 1992; 126: 88
   Google Scholar
• Neumann F. Chemische Konstitution und pharmakologische Wirkung. Handbook of Exp. Pharmacology 23, Part I: Die Gestagene , K. Junkmann. Springer-Verlag, Berlin Heidelberg New York 1968; 680–1025
   Google Scholar
• Landau R. L., Bergenstal D. M., Lugibihl K., Kascht M. E. The metabolic effects of progesterone in man. J. Clin. Endocrinol. Metab. 1955; 15: 1194–215
   PubMed Web of Science ®Google Scholar
• Landau R. L., Lugibihl K. The catabolic and nutriuretic effects of progesterone in man. Recent. Progr. Horm. Res. 1961; 17: 249–92
   PubMedGoogle Scholar
• Elger W., Beier S. Überlegungen zur Bedeutung unterschiedlicher hormonaler Wirkungsspektren von Gestagenen. Aktuelle Aspekte der hormonalen Kontrazeption, J. Hammer-stein, 1982; 1993, Excepta Med., 4.36, 9–27
   Google Scholar
• Dorfman R. I. Antiandrogens in a castrated mouse test. Steroids 1963; 2: 185–93
   Google Scholar
• Ettinger B., Golditch I. M. Medroxyprogesterone acetate for the evaluation of hypertestosteronism in hirsute women. Fertil. Steril 1977; 28: 1285–90
   PubMedGoogle Scholar
• Gordon G. G., Southern A. L., Calanog A. The effect of medroxyprogesterone acetate on androgen metabolism in the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 1972; 35: 444–9
   PubMed Web of Science ®Google Scholar
• Bazin B., Thenevot R., Bursaux C., Paris J. Effects of nomegestrole-acetate, a new 19-nor-progesterone derivate, on pituitary-ovarian function in women. Br. J. Obstet. Gynaecol. 1987; 94: 1199–24
   PubMedGoogle Scholar
• Botella J. Interaction of a new 19-nor-progesterone derivative with progestagen miner-alcorticoid receptors. J. Pharmacol. 1986; 17: 698–701
   Google Scholar
• Botella J. The cellular mechanism of the antiandrogenic action of nomegestrol acetate a new 19-nor-progesterone on the rat prostate. Acta Endocrinol. 1987; 115: 544–8
   PubMedGoogle Scholar
• Oelkers W., Berger V., Bolik A., et al. Dihydrospirorenone, a new progestogen with antimineralcorticoid activity: effects on ovulation, electrolyte excretion, and the renin-aldosterone system in normal women. J. Clin. Endocrinol. Metab. 1991; 73: 837–42
   PubMed Web of Science ®Google Scholar
• Muhn P., Krattenmacher R., Beier S., Elger W., Schillinger E. Drospirenone: a novel progestogen with antimineralcorticoid and antiandrogenic activity. Contraception 1995; 51: 99–110
   PubMed Web of Science ®Google Scholar
• Lemay A., Dewailly S. D., Granier R., Huard J. Attenuation of mild hyper-androgenic activity in postpubertal acne by a triphasic oral contraceptive containing low doses of ethynyl estradiol andd, l-norgestrel. J. Clin. Endocrinol. Metab. 1990; 71: 8–14
   PubMed Web of Science ®Google Scholar
• Robinson G. E., Bounds W., Mackie I. J., Stocks J., Machin S. J., Guillebaud J. Changes in metabolism induced by oral contraceptives containing desogestrel in older women. Contraception 1990; 42: 263–73
   PubMed Web of Science ®Google Scholar
• Givens J. R., Andersen R. N., Wiser W. L., Fish S. A. Dynamics of suppression and recovery of plasma FSH, LH, androstenedione and testosterone in polycystic ovarian disease using an oral contraceptive. J. Clin. Endocrinol. Metab. 1974; 38: 727
   PubMed Web of Science ®Google Scholar
• Raj S. G., Raj M. H. G., Talbert L. M., Sloan C. S., Hicks B. Normalization of testosterone levels using a low-dose estrogen containing oral contraceptive in women with polycystic ovary syndrome. Obstet. Gynecol. 1982; 60: 15–19
   PubMed Web of Science ®Google Scholar
• Wild R. A., Umstot E. S., Andersen R. R., Givens G. R. Adrenal function in hirsutism: effect of an oral contraceptive. J. Clin. Endocrinol. Metab. 1982; 54: 676–81
   PubMed Web of Science ®Google Scholar
• Dewis P., Petsos P., Newman M., Anderson D. C. The treatment of hirsutism with a combination of desogestrel and ethinyl-estradiol. Clin. Endocrinol. 1985; 22: 29–36
   PubMed Web of Science ®Google Scholar
• Pugeat M. M., Dunn J. F., Nisula B. C. Transport of steroid hormones: interaction of 70 drugs with testosterone binding globulin and corticosteroid binding globulin. J. Clin. Endocrinol. Metab. 1981; 53: 69–75
   PubMed Web of Science ®Google Scholar
• Drugs and Therapeutics Bulletin. Starting oral contraceptives: which, when and how?. Drugs Ther. Bull. 1992; 30: 41–4
   PubMedGoogle Scholar
• Porcile A., Gallardo E. Long-term treatment of hirsutism: desogestrel compared with cyproterone acetate in oral contraceptives. Fertil. Steril 1991; 55: 877–81
   PubMed Web of Science ®Google Scholar
• Karpas A. E. The adrenal as source of androgens. The Course and Management of Hirsutism , R. B. Greemblatt, V. B. Mahesh, R. D. Gambrell. Parthenon Publishing, Carnforth 1987; 99–115
   Google Scholar
• Abraham G. E., Maroulis G. B., Boyers S. P., Buster J. E., Magyar G. M., Elner C. W. Dexamethasone suppression test in the management of hyperandrogenized patients. Obstet. Gynecol. 1981; 57: 158–65
   PubMed Web of Science ®Google Scholar
• Casey J. H., Burger H. D., Kent J. R., Kellie A. E., Moxham A., Nabarro J., Nabarro J. D. N. Treatment of hirsutism by adrenal and ovarian suppression. J. Clin. Endocrinol. Metab. 1966; 26: 1370–4
   PubMed Web of Science ®Google Scholar
• Redmond G. P., Gidwani G. P., Gupta M. K., Bedcos N. M., Parker R., Skibanski C., Bergfield W. Treatment of androgenic disorders with dexamethasone: dose-response relationship for suppression of dehydroepian-drosterone sulfate. J. Am. Acad. Dermatol. 1990; 22: 91–3
   PubMed Web of Science ®Google Scholar
• Spritzer P., Billaund L., Thalabard J. K., Birman P., Mowszowicz I., Raux-Demay M. C., Clair F., Kutten F., Mauvais-Jarvis P. Cyproterone acetate versus hydrocortisone treatment in late onset adrenal hyperplasia. J. Clin. Endocrinol. Metab. 1990; 70: 642–6
   PubMed Web of Science ®Google Scholar
• Casey J. K., Burgher H. G., Kent J. R., Kellie A. E. Treatment of hirsutism by adrenal and ovarian suppression. J. Clin. Endocrinol. Metab. 1966; 26: 1370
   PubMed Web of Science ®Google Scholar
• Girard J., Baumann J. B., Buhler U., Zuppinger K., Haas H. G., Staubb J. J., Wiss H. I. Cyproterone and ACTH adrenal function. J. Clin. Endocrinol. Metab. 1978; 47: 581–5
   PubMed Web of Science ®Google Scholar
• Jeffcoate W. J., Rees L. H., Edwards C. R. W., Besser G. M. Cyproterone acetate and its effect on ACTH secretion. Lancet 1976; 1: 1140–2
   Google Scholar
• Girard J., Baumann J. B., Bohler U., Zuppinger K., Haas H. G., Staub J. J., Wyss H. I. Cyproterone acetate and ACTH adrenal function. J. Clin. Endocrinol. Metab. 1978; 47: 581–5
   Google Scholar
• Higuchi K., Nawata H., Maki T., Hagashizima M., Kato K. I., Ibayashi H. Prolactin has a direct effect on adrenal androgen secretion. J. Clin. Endocrinol. Metab. 1984; 59: 714–18
   PubMed Web of Science ®Google Scholar
• Serafini P., Lobo R. A. Prolactin modulates peripheral androgen metabolism. Fertil. Steril. 1986; 45: 41–4
   PubMedGoogle Scholar
• Ho K. Y., Thorner M. O. Therapeutic applications of bromocriptine in endocrine and neurological diseases. Drugs 1988; 36: 67–82
   PubMed Web of Science ®Google Scholar
• Crosignani P. G., Ferrari C. Dopaminergic treatments for hyperprolactinaemia. Bailliere's Clin. Obstet. Gynecol. 1990; 4: 441–55
   PubMed Web of Science ®Google Scholar
• Vance M. L., Evans W. S., Thorner M. O. Drugs five years later: bromocriptine. Ann. Int. Med. 1984; 100: 78–91
   PubMed Web of Science ®Google Scholar
• VanderHeijden P. F. M., de Wit W., Brownell J., Shoemaker J., Rolland R. CV 205-502, a new dopamine agonist, versus bromocriptine in the treatment of hyperprolactinaemia. Eur. J. Obstet. Gynecol. Reprod. Biol. 1991; 40: 111–18
   PubMedGoogle Scholar
• Webster J., Piscitelli G., Polli A., Ferrari C. I., Ismail I., Scanlon M. F. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N. Engl. J. Med. 1994; 331: 904–9
   PubMed Web of Science ®Google Scholar
• Ferrari C., Paracchi A., Mattei A. M., de Vincentiis S., D'Alberton A., Crosignani P. G. Cabergoline in the long-term therapy of hyperprolactinemic disorders. Acta Endocrinol. (Copenh). 1992; 126: 489–94
   PubMedGoogle Scholar
• Sawers R. A., Randall V. A., Iqbal M. J. Studies on the clinical and endocrine aspects of antiandrogens. Androgens and Antiandrogens Therapy. Current Topics in Endocrinology , S. L. Jeffcoate. John Wiley, Chichester 1982; 1: 145–68
   Google Scholar
• Neumann F., Graf K. J., Hasan S. H., Schench B., Steimbeck H. Central action of antiandrogens. Androgens and Antiandrogens , L. Martini, M. Motta. Raven Press, New York 1977; 163–77
   Google Scholar
• Dorfman R. I. Biological activity of antiandrogens. Br. J. Dermatol. 1970; 82: 3–8
   Google Scholar
• Hammerstein J., Cupceancu B. Behandlung des Hirsutismus mit Cyproterona-cetat. Dtsch. Med. Wochenschr. 1969; 94: 829–34
   PubMed Web of Science ®Google Scholar
• Hammerstein J., Meckies J., Leo-Rossberg I., Moltz L., Zielske I. Use of cyproterone acetate in the treatment of acne, hirsutism and virilism. J. Steroid Biochem. 1975; 6: 827–36
   PubMedGoogle Scholar
• Hammerstein J., Cupceancu B. The treatment of hirsutism with cyproterone acetate. Germ. Med. Monthly 1969; 14: 599–602
   PubMedGoogle Scholar
• Mowszowicz I., Raihi M., Wright M. Androgen receptors in human skin cyto-solj. Clin. Endocrinol. Metab. 1981; 52: 338–44
   Google Scholar
• Neumann F., Schleusener A. Pharmacology of cyproterone acetate with special reference to the skin. Proceedings of the Diane symposium, N. Vokaer, D. Fanta. Excerpta Medica, Brussels, Amsterdam 1980; 19–51
   Google Scholar
• Mowsowicz I., Wright F., Vincens M. Androgen metabolism in hirsute females treated with cyproterone acetate. J. Steroid Biochem. 1984; 20: 757–61
   PubMedGoogle Scholar
• Kutten F., Mowsowicz I., Mauvais-Jarvis P. Androgen metabolism in human skin. Percutaneous Absorption of Steroids , P. Mauvais-Jarvis, C. Vickers, J. Wepierre. Academic Press, London 1980; 99–121
   Google Scholar
• Jasonni V. M., Di Cosmo E., Bulletti C., Cappuccini F., Naldi S., Flamigni C. Treatment of hirsutism by an association of oral cyproterone acetate and transdermal b˜-estradiol. Fertil. Steril 1991; 55: 742–5
   PubMed Web of Science ®Google Scholar
• Schmidt J. B., Hber J., Spona J. Parenteral and oral cyproterone acetate treatment in severe hirsutism. Gynaecol. Obstet. Invest. 1987; 24: 125–30
   PubMed Web of Science ®Google Scholar
• Marcondes A. M., Wajchemberg B. L., Abu-jamra A. C., Luthold W. W., Samojlik E., Kirschner M. A. Monthly cyproterone acetate in the treatment of hirsute women: clinical and laboratory effects. Fertil. Steril. 1990; 53: 40–4
   PubMed Web of Science ®Google Scholar
• Belisle S., Love E. G. Clinical efficacy and safety of cyproterone acetate in severe hirsutism: results of multicenter Canadian study. Fertil. Steril. 1986; 46: 115–20
   Google Scholar
• Barth J. H., Cherry C. A., Wojnarowska F., Dawber R. P. R. Cyproterone acetate for severe hirsutism: results of a double blind dose-ranging study. Clin. Endocrinol. 1991; 35: 5–10
   PubMed Web of Science ®Google Scholar
• Holdaway I. M., Croxsom M. S., Ibbotson H. K. Cyproterone acetate as initial treatment and maintenance therapy for hirsutism. Acta Endocrinol. 1985; 109: 522–9
   PubMedGoogle Scholar
• Porcile A., Gallardo E. Oral contraceptives containing desogestrel in the maintenance of the remission of hirsutism: monthly versus bimonthly treatment. Contraception 1991; 44: 533–9
   PubMed Web of Science ®Google Scholar
• Seed M., Godsland I. F., Wynn V., Jacobs H. S. The effects of cyproterone acetate and ethinyl oestradiol on carbohydrate metabolism. J. Clin. Endocrinol. Metab. 1984; 51: 231–6
   Google Scholar
• Vermeulen A., Rubens R. Effects of cyproterone acetate plus ethinylestradiol low dose on plasma androgens and lipids in mildly hirsute or acneic young women. Contraceptive 1990; 28: 167–71
   Google Scholar
• Noguchi S., Nishizama J., Uchida N. Stimulatory effect of physiological doses of androgens or pharmacological doses of estrogens on growth of Shinogi carcinoma 115 in mice. Cancer Res. 1985; 45: 546–60
   PubMed Web of Science ®Google Scholar
• Luthy L. A., Begin D. J., Labrie F. Androgenic activity of synthetic progestins and spironolactone in androgen-sensitive mouse mammary carcinoma (Shinogi) cells in culture. J. Steroid Biochem. 1988; 31: 845–52
   PubMedGoogle Scholar
• Plante M., Lapointe S., Labrie F. Stimulatory effect of synthetic progestins currently used for the treatment of prostate cancer on growth of the androgen-sensitive Shinogi tumor in mice. J. Steroid Biochem. 1988; 52: 338–44
   Google Scholar
• Labrie C., Cusan L., Plante M. Analysis of the androgenic activity of synthetic “progestins” currendy used for the treatment of prostate cancer. J. Steroid Biochem. 1987; 28: 379–84
   PubMedGoogle Scholar
• Bressollette L., Dubois A., Carlhant D., Morand C., Mottier D., Riche C. Fatal hepatitis caused by cyproterone acetate. Therapie 1994; 49: 153–5
   PubMedGoogle Scholar
• Hirsch D., Kovatz S., Bernheim J., Shenk-man L. Fatal fulminant hepatitis from cyproterone acetate. Isr. J. Med. Sri. 1994; 30: 238–40
   PubMedGoogle Scholar
• Roila F., Crino L., Carloni G., Natalini G. Cyproterone acetate: hepatoxicity and prostatic cancer treatment. Ann. Oncol. 1993; 4: 701–4
   PubMedGoogle Scholar
• Gerlyng P., Grotmol T., Seglen P. O. Effect of 4-acetylaminofluorence and other tumor promoter on hepatocellular growth and binucleation. Carcinogenesis 1994; 15: 371–9
   PubMed Web of Science ®Google Scholar
• Kattan J., Spatz A., Culine S., Terrier-Lacombe M. J., Elias D., Droz J. P. Hepatocellular carcinoma during hormonotherapy for prostatic cancer. Am. J. Clin. Oncol. 1994; 17: 390–2
   PubMedGoogle Scholar
• Roberts R. A., Soames A. R., Gill J. H., James N. H., Wheeldon E. B. Non-genotoxic hepatocarcinogens stimulate DNA synthesis and their withdrawal induced apoptosis, but in different hepatocyte populations. Carcinogenesis 1994; 16: 1693–8
   Web of Science ®Google Scholar
• Topinka J., Binkowa B., Zhu H. K., Andrae U., Neumann I., Schwarz L. R., Werner S., Wolff T. DNA-damaging activity of the cyproterone acetate analogues chlormadinone acetate and megestrol acetate in rat liver. Carcinogenesis 1995; 16: 1483–7
   PubMed Web of Science ®Google Scholar
• Rudiger T., Beckmann J., Queisser W. Hepatocellular carcinoma after treatment with cyproterone acetate combined with ethinyl-oestradiol. Lancet 1995; 18: 452–3
   Google Scholar
• Hammerstein J., Rabe T., Runnebaum B. Position of the German Society of Gynecology and Obstetrics on the intended recall of approved CPA-containing drugs. Gynakol. Ceburtshilfliche Rundsch. 1995; 35: 49–50
   PubMedGoogle Scholar
• Corvol P., Michaud A., Menard J. Antiandrogenic effect of spironolactone: mechanism of action. Endocrinology 1975; 46: 1015–20
   Google Scholar
• Eil C., Edelsen S. K. The use of skin fibroblasts to obtain potency estimates of drug binding to androgen receptors. J. Clin. Endocrinol. Metab. 1984; 59: 51–5
   Google Scholar
• Stripp B., Taylor A. A., Bartter F. C. Effect of spironolactone on sex hormones in man. J. Clin. Endocrinol. Metab. 1975; 41: 777–81
   PubMed Web of Science ®Google Scholar
• Evans D. J., Burke C. W. Spironolactone in the treatment of idiopathic hirsutism and polycystic ovary syndrome. J. R. Soc. Med. 1986; 79: 451–3
   PubMedGoogle Scholar
• Young R. L., Goldzieher J. W., Eckland-Hirsh K. The endocrine effects of spironolactone as an anti-androgen. Fertil. Steril. 1987; 48: 223–8
   PubMed Web of Science ®Google Scholar
• Menard R. H., Guenther T. M., Kol H., Gillette G. R. Studies on the destruction of adrenal and testicular cytochrome P-450 by spironolactone. J. Biol. Chem. 1979; 254: 1726–33
   Google Scholar
• Rose L. I., Underwood L. H., Newmark S. R. Pathophysiology of spironolactone-induced gynecomastia. Ann. Int. Med. 1977; 87: 397–403
   Google Scholar
• Cumming D. C., Yang G. C., Rebar R. W., Yen S. S. C. Treatment of hirsutism with spironolactone. JAMA 1982; 247: 1295
   PubMed Web of Science ®Google Scholar
• Evron S., Shapiro G., Diamant Y. Z. Induction of ovulation with spironolactone (aldactone) in anovulatory, oligomenorrheic women. Fertil. Steril. 1981; 36: 468–72
   PubMedGoogle Scholar
• Ylostalo P., Heikkinen J., Kauppila A., Pakari-nen A., Jarvinen P. A. Low-dose spironolactone in the treatment of female hirsutism. Int. J. Fertil. 1987; 32: 41–5
   PubMedGoogle Scholar
• Lobo R. A., Shoupe D., Serafini P., Brinton D., Horton R. The effects of two doses of spironolactone on serum androgens and anagen hair in hirsute women. Fertil. Steril. 1985; 43: 200–5
   PubMed Web of Science ®Google Scholar
• Callan A. W. Spironolactone therapy in hirsutism and acne. Aust. J. Dermatol. 1988; 29: 135–9
   Google Scholar
• McLellan A. R., Rentoul J., Mackie R., McLnnes G. T. Lack of effect of spironolactone on hair shaft diameter in hirsute females. Postgrad. Med. J. 1989; 65: 459–62
   PubMed Web of Science ®Google Scholar
• Renkes P., Gaucger P., Trechot P. Spironolactone and hepatic toxicity. JAMA 1995; 273: 376–7
   PubMed Web of Science ®Google Scholar
• Zapater P., Albba D. Acidosis and extreme hyperkalemia associated with cholestyramine and spironolactone. Ann. Phamtacother. 1995; 29: 199–200
   PubMed Web of Science ®Google Scholar
• Wild R. A., Demers L. M., Applebaum-Bowden D., Lenker R. Hirsutism: metabolic effects of two commonly used oral contraceptives and spironolactone. Contraception 1991; 44: 113–24
   PubMed Web of Science ®Google Scholar
• Berardesca E., Gabba P., Ucci G., Borroni G., Rabbiosi G. Topical spironolactone inhibits dihydrotestosterone receptors in human sebaceous glands: an autoradiographic study in subjects with acne vulgaris. Int. J. Reac 1988; X: 115–19
   Google Scholar
• Funder J. W., Mercer J. E. Cimeti-dine, a histamine H2 receptor antagonist, occupies androgen receptors. J. Clin. Endocrinol. Metab. 1979; 48: 189–91
   PubMed Web of Science ®Google Scholar
• Vigersky R. A., Mehlman I., Glass A. R., Smith S. E. Treatment of hirsute women with cimetidine. N. Engl. J. Med. 1980; 303: 1042–6
   PubMed Web of Science ®Google Scholar
• Lissak A., Sorpkin Y., Calderon I., Dirnfield M., Lioz H., Abramovici H. Treatment of hirsutism with cimetidine; a prospective randomized trial. Fertil. Steril. 1989; 51: 247
   PubMed Web of Science ®Google Scholar
• Eil C., Edelson S. K. The use of human skin fibroblasts to obtain potency estimates of drug binding to androgen receptors. J. Clin. Endocrinol. Metab. 1984; 59: 51–5
   PubMed Web of Science ®Google Scholar
• Heel R. C., Brogden R. N., Carmine A., Morley P. A., Speigh T. M., Avery G. S. Ketoconazole: a review of its therapeutical efficacy in superficial and systemic fungal infections. Drugs 1982; 23: 1–36
   PubMed Web of Science ®Google Scholar
• Pont A., Williams P. L., Azhar S. Ketoconazole blocks testosterone synthesis. Arch Int. Med. 1982; 142: 2137
   PubMed Web of Science ®Google Scholar
• Feldmann D. Ketoconazole and other imidazole derivatives as inhibitors of steroidogenesis. Endocr. Rev. 1986; 7: 409
   PubMed Web of Science ®Google Scholar
• Santen R. J., Van den Bossche H., Symoens J., Brugmans J., De Coster R. Site of action of low dose ketoconazole on androgen biosynthesis in men. J. Endocrinol. Metab. 1983; 57: 732–6
   PubMed Web of Science ®Google Scholar
• Lamberts S. W. J., Bons E. G., Bruining H. A., Dejong F. H. Differential effects of the imidazole derivatives etomidate, ketoconazole and miconazole and of metyrapone on the secretion of Cortisol and its precursors by human adrenocortical cells. J. Pharmacol. Exp. 1987; 240: 259
   PubMed Web of Science ®Google Scholar
• McCance D. R., Hadden D. R., Kenne Y. L., Sheridan B., Atkinson A. B. Clinical experience with ketoconazole as therapy for patients with Cushing's syndrome. Clin. Endocrinol 1987; 27: 593
   PubMed Web of Science ®Google Scholar
• Boscaro N., Sonino M., Rampazzo A., Mantero F. Response ofpituitary-adrenal axis to corticotropin releasing-hormone in patients with Cushing's disease before and after ketoconazole treatment. Clin. Endocrinol. 1987; 27: 461
   PubMed Web of Science ®Google Scholar
• Loli P., Berselli M. E., Tagliaferri M. Use of ketoconazole in the treatment of Cushing's syndrome. J. Clin. Endocrinol. Metab. 1986; 63: 1365
   Google Scholar
• Sonino N. Current trends in the endocrine use of ketoconazole. J. Endocrinol. Invest. 1988; 11: 741
   PubMed Web of Science ®Google Scholar
• Conget J. I., Halperin I., Ferrer J., Gonzales-Clemente J. M., Martinez-Osabam M. J., Vilardell E. Evaluation of clinical and hormonal effects in hirsute women treated with ketoconazole. J. Endocrinol. Invest. 1990; 13: 867–70
   PubMed Web of Science ®Google Scholar
• Carvalho D., Pignatelli D., Resende C. Ketoconazole for hirsutism. Lancet 1985; II: 560
   Google Scholar
• Akalin S. Effects of ketoconazole in hirsute women. Acta Endocrinol. (Copenh.) 1991; 124: 19–22
   PubMedGoogle Scholar
• Martikainen J., Heikkinen J., Ruokonen A., Kauppilia A. Hormonal and clinical effects of ketoconazole in hirsute women. J. Endocrinol. Metab. 1988; 66: 987–91
   PubMed Web of Science ®Google Scholar
• Lewis J. H., Zimmermann H. J., Benson G. D., Ishak K. G. Hepatic injury associated with ketoconazole therapy: analysis of 33 cases. Gastroenterology 1984; 86: 503–13
   PubMed Web of Science ®Google Scholar
• Lake-Bakaar G., Scheuer S., Sherlok S. Hepatic reactions associated with ketoconazole in the United Kingdom. Br. Med. J. 1987; 294: 419–22
   PubMed Web of Science ®Google Scholar
• Mecnair A. L., Gascoigne E., Heap J., Schuermans V., Symoens J. Hepatitis and ketoconazole therapy. Br. Med. J. 1981; 283: 1058
   PubMedGoogle Scholar
• Peter R. U., Richarz-Barthauer U. Successful treatment and prophylaxis of scalp seborrheic dermatitis and dandruff with 2% ketoconazole shampoo: results of a multicentre, double-blind, placebo-controlled trial. Br. J. Dermatol. 1995; 132: 441–5
   PubMed Web of Science ®Google Scholar
• Neri B., Bartalucci S., Pieri A., Gemelli M. T., Rizzo M., Bartoletti R., Trippitelli A., Paoletti M. C. Complete androgen blockade as treatment for advanced prostate cancer: clinical response and side-effects. Anticancer Res. 1989; 9: 13
   PubMed Web of Science ®Google Scholar
• Neri R., Kassem N. Biological and clinical properties of antiandrogens. Progress in Cancer Research and Therapy , A. Bresciani. Raven Press, New York 1984; 31
   Google Scholar
• Teutsch G., Goubet F., Battmann T., Bonfils A., Bochoux F., Cerede E., Gofllo D., Gaillard-Kelly T., Philibert D. Non-steroidal antiandrogens: synthesis and biological profile of high affinity ligands for the androgen receptor. J. Steroid Biochem. 1994; 48: 111–19
   Google Scholar
• Peets E. A., Henson M. F., Neri R. On the mechanism of the anti-androgenic action of flutamide (α-α-α-trifluoro-2-methyl-nitro-m-propionotoluidide) in the rat. Endocrinology 1974; 94: 532–40
   PubMed Web of Science ®Google Scholar
• Liao S., Kohowell D., Chang T. M. Action of nonsteroidal antiandrogen flutamide on the receptor binding and nuclear retention of 5-α-dihydro-testosterone in rat ventral prostate. Endocrinology 1974; 94: 1205
   PubMed Web of Science ®Google Scholar
• Irwin R. J., Prout G. R. A new antiprostatic agent for treatment of prostatic carcinoma. Surg. Forum 1976; 24: 536–8
   Google Scholar
• Daricello G., Serretta V., Pavone-Macaluso M. Flutamide in the treatment of advanced prostatic cancer. J. Drug Dev. 1987; 1: 17–22
   Google Scholar
• Sogani P. C., Vagaiwala M. R., Whitmore W. F. Experience with flutamide in patients with advanced prostatic carcinoma without prior endocrine therapy. Cancer 1984; 54: 744–50
   PubMed Web of Science ®Google Scholar
• Couzinet B., Pholsena M., Young J., Schaison G. The impact of a pure antiandrogen (flutamide) on LH, FSH, androgens and clinical status in idiopathic hirsutism. Clin. Endocrinol 1993; 39: 157–62
   PubMed Web of Science ®Google Scholar
• Marcondes J. A. M., Minnani L. S., Luthold W. W., Wajchemberg B. L., Samojlik E. S., Kirschner M. A. Treatment of hirsutism in women with flutamide. Fertil. Steril. 1992; 57: 543–7
   PubMed Web of Science ®Google Scholar
• Cusan L., Dupont A., Bélanger A., Tremblay R., Manhes G., Labrie F. Treatment of hirsutism with the pure antiandrogen flutamide. J. Am. Ace. Dermatol. 1990; 23: 462–9
   PubMed Web of Science ®Google Scholar
• Presl J. Therapy of hirsutism with flutamide, a new non-steroidal antiandrogen. Ceska. Gynekol. 1994; 59: 275–6
   PubMedGoogle Scholar
• Motta T., Maggi G., Perra M., Azzolari E., Casazza S., D'Alberton A. Flutamide in the treatment of hirsutism. Int. J. Gynecol. Obstet. 1991; 36: 155–7
   PubMed Web of Science ®Google Scholar
• Pucci E., Genazzani A. D., Monzani F., Lippi F., Angelini F., Gargani M., Barletta D., Luisi M., Genazzani A. R. Prolonged treatment of hirsutism with flutamide alone in patients affected by polycystic ovary syndrome. Gynecol. Endocrinol. 1995; 9: 221–8
   PubMed Web of Science ®Google Scholar
• Marugo M., Bernasconi D., Meozzi M., Del Monte P., Zino V., Primarolo P., Barda-racco B. The use of flutamide in the management of hirsutism. J. Endocrinol. Invest. 1994; 17: 195–9
   PubMed Web of Science ®Google Scholar
• Balzano S., Cappa M., Migliari R., Scarpa R. M., Danielli E., Campus G., Pintus C., Sica V., Martino M. The effects of flutamide on basal and ACTH-stimulated plasma levels of adrenal androgens in patients with advanced prostate cancer. J. Endocrinol. Invest. 1988; 11: 693–6
   PubMed Web of Science ®Google Scholar
• Hellmann L., Bradlow H. L., Freed S., Levin J., Rosenfeld R. S., Withmore W. F., Zumoff B. The effect of flutamide on testosterone metabolism and the plasma levels of androgens and gonadotropins. J. Clin. Endocrinol. Metab. 1977; 45: 1224–9
   PubMed Web of Science ®Google Scholar
• Matzger D. L., Kerrigan J. R. Androgen receptor blockade with flutamide enhances growth hormone secretion in late pubertal males: evidence for independent actions of estrogen and androgen. J. Clin. Endocrinol. Metab. 1993; 76: 1147–52
   Google Scholar
• Wysowsky D. K., Fourcroy J. L. Flutamide hepatotoxicity. J. Urol. 1996; 155: 226–7
   PubMed Web of Science ®Google Scholar
• Kosar J., Sasmaz N., Oguz P., Kucukbas S. Hepatic insufficiency developing as a result of flutamide treatment. Am. J. Gastroenterol. 1995; 90: 1027–8
   PubMed Web of Science ®Google Scholar
• Poyet P., Labie F. Comparison of antiandrogen/androgenic activities of flutamide, cyproterone acetate and megestrol acetate. Mol. Cell. Endocrinol. 1985; 42: 238–8
   Web of Science ®Google Scholar
• Knuth U. A., Hano R., Nieschlag E. Effect of flutamide or cyproterone acetate on pituitary and testicular hormones in normal men. J. Clin. Endocrinol. Metab. 1984; 59: 963–8
   PubMed Web of Science ®Google Scholar
• Eremus M. Efficacy of flutamide versus spironolactone. Fertil. Steril. 1993; 63: 680
   Web of Science ®Google Scholar
• Eremus M., Garbuz O., Durmusoglu F., Demirkay Z., Pekin S. Comparison of the efficacy of spironolactone versus flutamide in the treatment of hirsutism. Fertil. Steril. 1994; 61: 613–16
   PubMed Web of Science ®Google Scholar
• Eri L. M., Tveter K. J. Aprospective, placebo controlled study of the antiandrogen casodex as treatment for patients with benign prostatic hyperplasia. Br. J. Urol. 1993; 150: 90–4
   Google Scholar
• Eri L. M., Haug E. Effects on endocrine system of long-term treatment with nonsteroidal anti-androgen casodex in patients with benign prostate hyperplasia. Br. J. Urol. 1995; 75: 335–40
   PubMedGoogle Scholar
• Teutsch G., Goubet F., Battmann T., Bonfils A., Bouchoux F., Cerede E., Gofflo D., Gaillard-Kelly M., Philibert D. Non steroidal antiandrogens: synthesis and biological profile of high-affinity ligands for the androgen receptor J. Steroid. Biochem. Mol. Biol. 1994; 48: 11–19
   Web of Science ®Google Scholar
• Chan H. C., Geissler W. M., Anderson S. Characterization of human steroid 5a-reductase types I and II expressed in the baculo-virus system. Sex Hormone and Antihonnones in Endocrine Dependent Pathology: Basic and Clinical Aspects , M. Motta, M. Serio. Elsevier Science B. V., Amsterdam 1994; 67–76
   Google Scholar
• Gilad S., Chayen R., Tordjman K., Kisch E., Stern N. Assessment of 5 alpha-reductase activity in hirsute women: comparison of serum androstanediol glucuronide with urinary androsterone and aetiocholanolone excretion. Clin. Endocrinol. (Oxf.) 1994; 40: 459–64
   PubMed Web of Science ®Google Scholar
• Rittmaster R. S. Finasteride. N. Engl. J. Med. 1994; 13: 120–5
   Google Scholar
• Ciotta L., Cianci A., Calogero A. E., Palumbo M. A., Marietta E., Sciuto A., Palumbo G. Clinical and endocrine effects of finasteride, a 5 alpha-reductase inhibitor, in women with idiopathic hirsutism. Fertil. Steril. 1995; 64: 299–306
   PubMed Web of Science ®Google Scholar
• Wong I. L., Morris R. S., Chang L., Spahan M. A., Stanczyk F. Z., Lobo R. A. A prospective randomized trial comparing finasteride to spironolactone in the treatment of hirsute women.]. Clin. Endocrinol. Metab. 1995; 80: 233–8
   Google Scholar
• Moghetti P., Castello R., Magnani C. M., Tosi F., Negri C., Armanini D., Bellotti G., Mugeo M. Clinical and hormonal effects of the 5 alpha-reductase inhibitor finasteride in idiopathic hirsutism. J. Clin. Endocrinol. Metab. 1994; 79: 1115–21
   PubMed Web of Science ®Google Scholar
• Fruzzetti F., de Lorenzo D., Parrini D., Ricci C. Effects of finasteride, a 5 alpha-reductase inhibitor, on circulating androgens and gonadotropin secretion in hirsute women. J. Clin. Endocrinol. Metab. 1994; 79: 831–5
   Google Scholar
• Levy M. A., Brandt M., Dinh J. T., Hok D. A., Garrison L. M., Bergsma D. J., Metcalf B. W. Epristeride is a selective and specific uncompetitive inhibitor of human steroid 5 alpha-reductase isoform 2. Steroid. Biochem. Mol. Biol 1994; 48: 197–206
   PubMed Web of Science ®Google Scholar
• Giudici G., Briatico G., Biagini L., Cominato C. Effect of 5-reductase inhibitor, turosteride, finasteride and epristeride on prostatic testosterone and dihydrotestosterone in the rat. J. Endocrinol. Invest. 1994; 17: 51
   PubMedGoogle Scholar
• Di Salle E., Briatico G., Giudici G., Ornati G., Panzeri A. Endocrine properties of the 5 alpha-reductase inhibitor turosteride. J. Steroid Biochem. Mol. Biol. 1994; 48: 241–8
   PubMed Web of Science ®Google Scholar
• Gjonnaess H. Polycystic ovarian syndrome treated by ovarian electrocautery through the laparoscope. Fertil. Steril. 1984; 41: 20–5
   PubMed Web of Science ®Google Scholar
• Katz M., Carr P. J., Cohen B. M. Hormonal effects of wedge resection of polycystic ovaries. Obstet. Gynecol. 1978; 51: 437–52
   PubMed Web of Science ®Google Scholar
• Mahesh V. B., Toledo S. P. A., Mattar E. Hormonal levels following wedge resection in polycystic ovary syndrome. Obstet. Gynecol. 1978; 51: 64–8
   Web of Science ®Google Scholar
• Judd H. L., Rigg L. A., Anderson D. C. The effects of ovarian wedge resection on circulating gonadotropin and ovarian steroid levels in patients with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 1976; 43: 347–50
   PubMed Web of Science ®Google Scholar
• Archard C., Thiers J. Le virilisme pilaire et son association à ľinsufFisance glycoly-tique. Bull. Acad. Nat. Med. 1921; 86: 51–5
   Google Scholar
• Kahn C. R., Filier J. S., Bar R. S., Archer J. A., Gorden P., Martin M. M., Roth J. The syndromes of insulin resistance and acanthosis nigricans. Insulin-receptors disorders in man. N. Engl. J. Med. 1976; 294: 739–45
   PubMed Web of Science ®Google Scholar
• Kahn C. R., Filier G. S., Bar R. S., Archer J. A., Gorden P., Martin M. M., Roth J. The syndromes of insulin resistance and acanthosis nigricans. N. Engl. J. Med. 1976; 50: 113–16
   Google Scholar
• Rendon M., Cruz P. D., Sontheimer R. D., Bergstresser P. R. Acanthosis nigricans: a cutaneous marker for tissue resistance to insulin. J. Am. Acad. Dermatol. 1989; 21: 461
   PubMed Web of Science ®Google Scholar
• Cruz P. D., Huld J. A. Excess insulin binding insulin-like growth factor receptors: proposed mechanism for acanthosis nigricans. J. Invest. Dermatol. 1992; 98: 825
   Web of Science ®Google Scholar
• Marcelli J. M., Debussche X., Fendri S., Puy H., Arlot S. Obésité féminine: la testostéronémie est positivement corrélée à ľinsulinorésistance périférique. Ann. Endocrinol. (Paris) 1993; 45: 169–73
   Google Scholar
• Conway G. S., Jacobs H. S. Clinical implications of hyperinsulinemia in women. Clin. Endocrinol. 1993; 39: 623–32
   PubMed Web of Science ®Google Scholar
• Pedersen S. B., Borglum J. D., Schmitz O., Bak J. F., Sorensen N. S., Richelsen B. Abdominal obesity is associated with insulin resistance and reduced glycogen synthase activity in skeletal muscle. Metabolism 1993; 42: 998–1005
   PubMed Web of Science ®Google Scholar
• Conway G. S., Jacobs H. S., Holly G. M. P., Wass J. A. S. Effects of luteinizing hormone, insulin, insulin-like growth factor 1 and insulin-like growth factor small binding protein in the polycystic ovary syndrome. Clin. Endocrinol 1990; 33: 593–603
   PubMed Web of Science ®Google Scholar
• Barbieri R. L., Makris A., Randall R. W., Daniels G., Kistner R. W., Ryan K. J. Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism. J. Clin. Endocrinol. Metab. 1986; 62: 904
   PubMed Web of Science ®Google Scholar
• Davoren J. B., Kasson B. G., Li C. H., Hsueh A. J. W. Specific insulin-like growth factor (IGF) I- and II binding sites on rat granulosa cells: relation to IGF action. Endocrinology 1986; 119: 2155
   PubMed Web of Science ®Google Scholar
• Barbieri R. L., Makris A., Ryan K. Insulin stimulated androgen accumulation in incubations of human ovarian stroma and theca. Obstet. Gynecol. 1984; 64: 73–8
   PubMed Web of Science ®Google Scholar
• Garzo G., Dorrington J. H. Aromatase activity in human granulosa cells during follicular development and the modulation by follicle-stimulating hormone and insulin. Am. J. Obstet. Gynecol. 1984; 148: 657–61
   PubMed Web of Science ®Google Scholar
• Lino J., Baranao S., Hammond J. M. Multihormone regulation of steroidogenesis in cultured porcine granulosa cells: studies in serum-free medium. Endocrinology 1985; 116: 2143
   PubMed Web of Science ®Google Scholar
• Zapf J., Froesch E. R. Insulin-like growth factors/somatomedins: structure, secretion, biological actions and physiological role. Horm. Res. 1986; 24: 121
   PubMed Web of Science ®Google Scholar
• Poretsky L. On the paradox of insulin-induced hyperandrogenism in insulin-resistant states. Endocr. Rev. 1991; 12: 3
   PubMed Web of Science ®Google Scholar
• Nestler J. E., Powers L. P., Matt D. W., Stein-gold K. A., Plymate S. R., Rittmaster R. S., Clore J. N., Blackard W. J. A direct effect of hyperinsulinemia on serum sex hormone binding globulin levels in obese women with the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 1991; 72: 83
   PubMed Web of Science ®Google Scholar
• Kiddy D. S., Hamilton-Fairley D., Seppala M., Koistinen R., James V. H. T., Reed M. J., Franks S. Diet-induced changes in sex-hormone binding globulin and free testosterone in women with normal and polycystic ovaries: correlation with insulin and insulin-like growth factors-1. Clin. Endocrinol. 1989; 31: 757–63
   PubMed Web of Science ®Google Scholar
• Pasupuleti V., Horton R. Insulinlike growth factor can alter steroid 5-a-reductase activity and formation of dihydrotestosterone in skin. Clin. Res. 1990; 38: 99
   Google Scholar
• Rosen O. M. Structure and function of insulin receptors. Diabetes 1989; 38: 1508
   PubMed Web of Science ®Google Scholar
• Bar R. S., Harrison L. C., Muggeo M., Gorden P., Kahn C. R., Roth J. Regulation of insulin receptors in normal and abnormal physiology in humans. Adv. Intern. Med. 1979; 24: 23
   PubMedGoogle Scholar
• Mosthaf L., Grako K., Dull T. J., Coussens L., Ullrich A., McClain D. A. Functionally distinct insulin receptors generated by tissue-specific alternative splicing. EMBOJ. 1990; 9: 2409
   PubMed Web of Science ®Google Scholar
• Geffner M. E., Golden D. W. Selective insulin action on skin, ovary, and heart in insulin resistant states. Diabetes Care 1988; 11: 500
   PubMed Web of Science ®Google Scholar
• Wagner R. F., Jr. Physical methods for the management of hirsutism. Cutis 1990; 45: 319
   PubMed Web of Science ®Google Scholar
• Schrioch E. A., Schrioch E. D. Treatment of hirsutism. Clin. Obstet. Gynecol. 1991; 34: 852–63
   PubMed Web of Science ®Google Scholar
• Hinkel A. R., Lind R. W. Electrolysis, Termolysis and the Blend . Arroway Publ., California 1968; 27–35
   Google Scholar
• Ebling F. J. Hair Research, Status and Future Aspects , C. E. Orfanos, W. Montagna, D. Stuttgen. Springer-Verlag, Berlin 1981; 116–30
   Google Scholar
• Prelevic G. M., Wurzburgher M. I., Balint-Peric L. J., Nesic J. Inhibitory effect of sandostatin on secretion of luteinising hormone and ovarian steroid in polycystic ovary syndrome. Lancet 1990; 336: 900–3
   PubMed Web of Science ®Google Scholar
• Vos P., Croughs R. J. M., Thijssen J. H. H. Response of luteinizing hormone secreting pituitary adenoma to a long-acting somatostatin analogue. Acta Endocrinol. 1988; 118: 587–90
   PubMedGoogle Scholar
• Koerker D. T., Ruch W., Chideckel E., Palmer J., Goodner C. J., Ensick J., Gale C. C. Somatostatin hypothalamic inhibitor of the endocrine pancreas. Science 1974; 184: 482–4
   PubMed Web of Science ®Google Scholar
• Williams G., Fuessl H., Kraenzlin M., Bloom S. R. Post prandial effects of SMS 201-995 on gut hormones and glucose tolerance. Scand. J. Gastroenterol. 1986; 119: 73–83
   Google Scholar
• Prelevic M. G., Ginsburg J., Maletic D., Hardiman P., Okolo S., Balint-Peric L., Thomas M., Orskov H. The effects of somatostatin analogue octreotide on ovulatory performance in women with polycystic ovaries. Hum. Reprod. 1995; 10: 28–32
   PubMed Web of Science ®Google Scholar
• Prelevic M. G., Wurtzburger M. I., Balint-Peric L., Hardiman P., Okolo S., Maletic D., Ginsburg J. Effects of somatostatin analogue Octreotide, in polycystic ovary syndrome. Metabolism 1992; 41: 76–9
   PubMed Web of Science ®Google Scholar
• Caron P. H. Intramuscular injection of slow-release lanreotide (BIM 23014) in acromegalic patients previously treated with continuous subcutaneous infusion of octreotide. Eur. J. Endocrinol. 1995; 132: 320–5
   PubMed Web of Science ®Google Scholar
• Heron J., Kuhn M. Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog BIM 23014 in patients with acromegaly. J. Clin. Endocrinol. Metab. 1993; 76: 721–7
   PubMed Web of Science ®Google Scholar